In a phase I study (NCT02546921), MOv18 (IgE), a chimeric first-in-class IgE antibody, exhibits anti-tumor effectiveness in ovarian cancer patients, with transient urticaria being the most frequent side effect (62). Here, IGHE is linked to ovarian cancer.